MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
103.35
+0.03
+0.03%
After Hours: 103.37 +0.02 +0.02% 19:49 02/10 EST
OPEN
103.40
PREV CLOSE
103.32
HIGH
103.54
LOW
103.22
VOLUME
2.02M
TURNOVER
--
52 WEEK HIGH
103.54
52 WEEK LOW
38.81
MARKET CAP
19.72B
P/E (TTM)
-19.4377
1D
5D
1M
3M
1Y
5Y
1D
Soft Start For $10B-Plus M&A Deals In 2026
Seeking Alpha · 13h ago
Weekly Report: what happened at EXAS last week (0202-0206)?
Weekly Report · 1d ago
Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time.
Barron‘s · 4d ago
GENEOSCOPY: PTAB'S RULING CONFIRMS GENEOSCOPY'S LONG-HELD POSITION AND CLEARS PATH FOR CONTINUED COMMERCIALIZATION OF COLOSENSE
Reuters · 4d ago
Exact Sciences ticks higher amid reports HSR for Abbott deal expired
Seeking Alpha · 4d ago
Exact Sciences ‘applauds’ passage of MCED legislation
TipRanks · 02/03 19:40
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide
Barchart · 02/03 08:03
The Best Dividend King to Buy With $150
NASDAQ · 02/02 17:05
More
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Webull offers Exact Sciences Corp stock information, including NASDAQ: EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.